Drug resistance in Mycobacterium tuberculosis: Molecular mechanisms and laboratory susceptibility testing

Antituberculosis Chemotherapy

Volumn 10, Issue , 2011, Pages 128-144

  Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900562607     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000324630     Document Type: Chapter

References (105)

1. Schatz A, Bugie E, Waksman SA: Substance exhibiting activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med 1944;55:66-69.
2. Lehman J: Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946;250:15-16.
3. Pyle MM: Relative numbers of resistant tubercule bacilli in sputa of patients before and during treatment with streptomycin. Proc Mayo Clin 1947;22:465-473.
4. Medical Research Council: Treatment of pulmonary tuberculosis with streptomycin and paraamino salicylic acid. Br Med J 1950;ii:1073-1085.
5. Medical Research Council: Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis. Br Med J 1955;i:435-445.
6. Yeager R, Monroe WE, Dessaus FI: Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952;65:523-546.
7. Maggi NC, Pasqualucci CR, Ballota R, Sensi P: Rifampicin: a new orally active rifamycin. Chemotherapia 1966;11:285-292.
8. Thomas JP, Baughn CO, Wilkinson RG, Shephard RG: A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2'-(ethylenediimino)-di-l-butanol). Am Rev Respir Dis 1961;83:891-893.
9. British Medical Research Council: Controlled clinical trial of short-course (6 months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;i:1072-1085.
10. British Thoracic Association: A controlled trial of six month chemotherapy in pulmonary tuberculosis:second report results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982;126:460-462.
11. Mitchison DA: Mechanisms of the action of drugs in short-course chemotherapy. Bull Int Union Tuberc 1985;60:36-40.
12. Fox W, Ellard GA, Mitchison DA: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;10(suppl 2):S231-S279.
13. Connolly LE, Edelstein PH, Ramakrishnan L: Why is long-term therapy required to cure tuberculosis? PLoS Med 2007;4:e120.
14. David HL: Probability distribution of drugresistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970;20:810-814.
15. Ramaswamy S, Musser JM: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc Lung Dis 1998;79:3-29.
16. Wade MM, Zhang Y: Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci 2004;9:975-994.
17. Pym AS, Cole ST: Mechanisms of drug resistance in Mycobacterium tuberculosis; in Wax RG, Lewis K, Salyers AA, Taber H (eds): Bacterial Resistance to Antimicrobials, ed 2. Boca Raton, CRC Press-Taylor & Francis Group, 2008, pp 313-342.
18. Böttger EC: Mechanisms of mycobacterial drug resistance: implications for treatment and prevention strategies. Chemotherapy 2006;15:23-28.
19. Böttger EC, Springer B: Tuberculosis: drug resistance, fitness and strategies for global control. Eur J Pediatr 2008;167:141-148.
20. Meier A, Kirschner P, Bange FC, Vogel U, Böttger EC: Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother 1994;38:228-233.
21. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE, Stover CK: Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996;272:1641-1643.
22. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Böttger EC: Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010;77:830-840.
23. Canetti G, Froman S, Grosset J, Hauduroy P, Langerová M, Mahler HT, Meissner G, Mitchison DA, Sula L: Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Org 1963;29:565-578.
24. Inderlied CB, Salfinger M: Antimicrobial agents and susceptibility tests: mycobacteria; in Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of Clinical Microbiology. Washington, American Society for Microbiology, 1995, pp 1385-1404.
25. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA:Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Org 1969;41:21-43.
26. Woodley CL: Evaluation of streptomycin and ethambutol concentrations for susceptibility testing of Mycobacterium tuberculosis by radiometric and conventional procedures. J Clin Microbiol 1986;23:385-386.
27. Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchuck B, Sloctsky, A, Washabange G, Mazurek G, Riddershof J: Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002;40:3976-3979.
28. Laszló A, Rahman M, Raviglione M, Bustreo F, WHO/IUATLD Network of Supranational Reference Laboratories: Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD supranational laboratory network: first round of proficiency testing. Int J Tuberc Lung Dis 1997;1:231-238.
29. Zhang Y, Heym B, Allen B, Young D, Cole S: The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-593.
30. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um SK, Wilson T, Collins, D, De Lisle G, Jacobs WR Jr: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-230.
31. Rouse DA, Li Z, Bai GH, Morris SL: Characterization of the katG and inhA genes of isoniazid resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:2472-2477.
32. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden, JD: Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and-susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996;173:196-202.
33. Dobner P, Rusch-Gerdes S, Bretzel G, Feldmann K, Rifai M, Loscher T, Rinder H: Usefulness of Mycobacterium tuberculosis genomic mutations in the genes katG and inhA for the prediction of isoniazid resistance. Int J Tuberc Lung Dis 1997;1:365-369.
34. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M: Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampicin. J Clin Microbiol 2006;44:4459-4463.
35. Marttila HJ, Soini H, Eerola E, Vyshnevskya E, Vyshnevskaya BI, Otten TF, Vasilyef AV, Viljanen MK: A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St Petersburg area in Russia. Antimicrob Agents Chemother 1998;42:2443-2445.
36. Van Soolingen D, Borgdorff MW, de Haas PE, Sebek MM, Veen J, Dessens M, Kremer K, van Embden JD: Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999;180:726-736.
37. Springer B, Calligaris-Maibach RC, Ritter C, Böttger EC: Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping. J Clin Microbiol 2008;46:4064-4067.
38. Springer B, Lucke K, Calligaris-Maibach RC, Ritter C, Böttger EC: Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009;47:1773-1780.
39. Gagneux S, Burgos MV, De Riemer K, Encisco A, Muñoz S, Hopewell PC, Small PM, Pym AS: Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006;2:e61.
40. Bergval IL, Schuitema AR, Klatser PR, Anthony RM: Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 2009;64:512-523.
41. Afanas'ev MV, Ikryannikova LN, Il'ina EN, Sidorenko SV, Kuz'min AV, Larionova EE, Smirnova, TG, Chernousova LN, Kamaev EY, Skorniakov SN, Kinsht VN, Cherednichenko AG, Govorun VM: Molecular characteristics of rifampicin-and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. J Antimicrob Chemother 2007;59:1057-1064.
42. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole ST, Colston MJ, Matter L, Schopfer K, Bodmer T: Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-650.
43. Huitric E, Werngren J, Juréen P, Hoffner S: Resistance levels and rpoB gene mutations among in vitro-selected rifampicin-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2006;50:2860-2862.
44. Takayama K, Kilburn JO: Inhibition of synthesis of arabinogalactane by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989;33:1493-1499.
45. Telenti A, Philipp WJ, Screevatsan S, Bernasconi C, Stockbauer KE, Wieles B, Musser JM, Jacobs WR Jr: The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997;3:567-570.
46. Johnson R, Jordaan AM, Pretorius L, Engelke E, van der Spuy G, Kewley C, Bosman M, van Helden PD, Warren R, Victor TC: Ethambutol resistance testing by mutation detection. Int J Tuberc Lung Dis 2006;10:68-73.
47. Starks AM, Gumusboga A, Plikaytis BB, Shinnick TM, Posey JE: Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009;53:1061-1066.
48. Safi H, Fleischmann RD, Peterson SN, Jones MB, Jarrahi B, Alland D: Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010;54:103-108.
49. Plinke C, Cox HS, Kalon S, Doshetov D, Rusch-Gerdes S, Niemann S: Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results. Tuberculosis 2009;89:448-452.
50. Scorpio A, Zhang Y: Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-667.
51. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y: Characterization of pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997;41:540-543.
52. Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, De Smet KA, Portaels F, van den Eeckhout E: Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2317-2319.
53. Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V: Characterization of new mutations in pyrazinamide resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase pncA. Antimicrob Agents Chemother 1999;43:1761-1763.
54. Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC:Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:2291-2295.
55. Zhang Y, Mitchison D: The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21.
56. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR Jr, Telenti A: Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-780.
57. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY: Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis:correlation with ofloxacin susceptibility. Microb Drug Res 2006;12:7-11.
58. Chan RC, Hui M, Chan EW, Au TK, Chin ML, Yip CK, Au Yeang CK, Yeung CY, Kam KM, Yip PC, Cheng AF: Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007;59:866-873.
59. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA:Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009;53:4498-500.
60. Matrat S, Aubry A, Mayer C, Jarlier V, Cambau E: Mutagenesis in the 34 GyrA helix and in the toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. Antimicrob Agents Chemother 2008;52:2909-2914.
61. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB: Treatment outcomes among patients with extensively drug-resistant tuberculosis. Clin Infect Dis 2010;51:6-14.
62. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, Veziris N: Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010;54:4765-4771.
63. Meier A, Heifets L, Wallace RJ Jr, Zhang Y, Brown BA, Sander P, Böttger EC: Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996;174:354-360.
64. De Barber AE, Mdluli K, Bosman M, Bekker, LG, Barry CE 3rd: Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000;97:9677-9682.
65. Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR Jr, Sacchettini JC: Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med 2007;204:73-78.
66. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC: ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003;47:3799-3805.
67. Hobbie SN, Bruell C, Kalapala S, Akshay S, Schmidt S, Pfister, P, Böttger EC: A genetic model to investigate drug-target interactions at the ribosomal decoding site. Biochimie 2006;88:1033-1043.
68. Finken M, Kirschner P, Meier A, Wrede A, Böttger EC: Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alteration of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993;9:1239-1246.
69. Sander P, Prammananan T, Böttger EC: Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol Microbiol 1996;22:841-848.
70. Meier A, Kirschner P, Springer B, Steingrube VA, Brown BA, Wallace RJ Jr, Böttger EC: Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994;38:381-384.
71. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, Böttger EC, Wallace RJ Jr: A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 1998;177:1573-1581.
72. Bercovier H, Kafri O, Sela S: Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem Biophys Res Commun 1986;136:1136-1141.
73. Springer B, Kidan YG, Prammananan T, Ellrott K, Böttger EC, Sander P: Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob Agents Chemother 2001;45:2877-2884.
74. Meier A, Sander P, Schaper KJ, Scholz M, Böttger EC: Correlation of molecular resistance mechanism and phenotypic resistance level in streptomycin-resistant M. tuberculosis. Antimicrob Agents Chemother 1996;40:2452-2454.
75. Honore N, Cole ST: Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994;38:238-242.
76. Sreevatsan S, Pan X, Stockbauer K, Williams D, Kreiswirth B, Musser JM: Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographical localities. Antimicrob Agents Chemother 1996;40:1024-1026.
77. Cooksey RC, Morlock GP, McQueen A, Glickman SE, Crawford JT: Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from New York City. Antimicrob Agents Chemother 1996;40:1186-1188.
78. Okamoto S, Tamaru A, Nakajima C, Nishimura K, Tanaka Y, Tokuyama S, Suzuki Y, Ochi K: Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol 2007;63:1096-1106.
79. Suzuki Y, Katsukava C, Tamaru A, Abe C, Makino M, Mizuguchi Y, Taniguchi H: Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Micobiol 1998;36:1220-1225.
80. Alangaden GJ, Kreiswirth B, Aouad A, Khetarpal M, Igno FR, Moghazeh SL, Manavathu EK, Lerner SA: Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:1295-1297.
81. Maus CE, Plikaytis BB, Shinnick TM: Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:3192-3197.
82. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L: High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009;53:5064-5068.
83. Zaunbrecher MA, Sikes RD, Metchock B, Shinnick TM, Posey JE: Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009;106:20004-20009.
84. Krüüner A, Jureen P, Levina K, Ghebremichael S, Hoffner S: Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:2971-2973.
85. Sutton WB, Gordee RS, Wick WE, Stanfield L: In-vitro and in-vivo laboratory studies on the antituberculous activity of capreomycin. Ann NY Acad Sci 1966;135:947-959.
86. Liou YF, Tanaka N: Dual actions of viomycin on the ribosomal functions. Biochem Biophys Res Commun 1976;71:477-483.
87. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S: Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. Mol Cell 2006;23:173-182.
88. Stanley RE, Blaha G, Grodzicki RL, Strickler MD, Steitz TA: The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat Struct Mol Biol 2010;17:289-293.
89. Tsukamura M: Cross-resistance relationships between capreomycin, kanamycin, and viomycin resistances in tubercle bacilli from patients. Am Rev Respir Dis 1969;99:780-782.
90. McClatchy JK, Kanes W, Davidson PT, Moulding TS: Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 1977;58:29-34.
91. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker A, Rüsch-Gerdes S, Niemann S: Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009;53:3353-3356.
92. Maus CE, Plikaytis BB, Shinnick TM: Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:571-577.
93. Vaddady PK, Lee RE, Meibohm B: In vitro pharmacokinetic/pharmacodynamic models in antiinfective drug development: focus on TB. Future Med Chem 2010;2:1355-1369.
94. Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA: Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009;64:786-793.
95. Victor TC, Warren R, Butt JL, Jordaan AM, Felix JV, Venter A, Sirgel FA, Schaaf HS, Donald PR, Richardson M, Cynamon MH, van Helden PD:Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. J Med Microbiol 1997;46:847-857.
96. Stewart SM, Crofton JW: The clinical significance of low degrees of drug resistance in pulmonary tuberculosis. Am Rev Respir Dis 1964;89:811-829.
97. Moulding TS: Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis 1981;123:262-264.
98. Cynamon MH, Zhang Y, Harpster T, Cheng S, De Stefano MS: High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 1999;43:2922-2924.
99. Tripathy SP, Menon NK, Mitchison DA, Narayana AS, Somasundaram PA, Stott H, Velu S: Response to treatment with isoniazid plus PAS of tuberculous patients with primary isoniazid resistance. Tubercle 1969;50:257-268.
100. Devadatta S, Bhatia AL, Andrews RH, Fox W, Mitchison DA, Radhakrishna S, Ramakrishnan CV, Selkon JB, Velu S: Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Org 1961;25:807-829.
101. Petty TL, Mitchell RS: Successful treatment of advanced isoniazid-and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide, and isoniazid. Am Rev Respir Dis 1962;86:503-512.
102. Böttger EC: Drug resistant tuberculosis. Lancet 2001;357:1288-1289.
103. NCCLS: Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard NCCLS document M24-A. Wayne, NCCLS, 2003.
104. Rinder H, Mieskes KT, Löscher T: Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2001;5:339-345.
105. Canetti G: Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965;92:687-703.